Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMK7XU)

• Drug Name: [3H]kainate Drug Info
• Synonyms: (2S,3S,4S)-3-(Carboxylatomethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylate; (2S,3S,4S)-3-(carboxylatomethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylate; GTPL4231; (2S,3S,4S)-3-(Carboxylatomethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylate; GTPL4085; KAINATE

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 73755076
  ChEBI ID: CHEBI:156548
  TTD Drug ID: DMMK7XU

Molecule-Related Drug Atlas

Drug(s) Targeting Glutamate receptor AMPA 1 (GRIA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
E-2007	DMJDYNQ	Diabetic neuropathy	8C0Z	Approved	[9]
NBQX	DMPHZI5	Neurological disorder	6B60	Phase 1	[10]
YM-90K	DMWRT4L	Convulsion	8A68.Z	Discontinued in Phase 2	[11]
Farampator	DM76GRQ	Major depressive disorder	6A70.3	Discontinued in Phase 1	[12]
GYKI-52466	DM3YG5P	Alzheimer disease	8A20	Terminated	[13]
GYKI-53655	DMC0JN8	N. A.	N. A.	Terminated	[14]
Zonampanel	DM70HZD	N. A.	N. A.	Terminated	[11]
SORETOLIDE	DMTDLHG	Convulsion	8A68.Z	Terminated	[15]
DNQX	DMQXPA5	Discovery agent	N.A.	Investigative	[16]
RPR-118723	DMLDWCB	Discovery agent	N.A.	Investigative	[17]

Drug(s) Targeting Adenosine A3 receptor (ADORA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IB-MECA	DM9G5XD	Psoriasis vulgaris	EA90	Phase 3	[18]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[19]
NITD609	DMQHBSX	Malaria	1F40-1F45	Phase 2	[20]
CF102	DMP56WJ	Hepatocellular carcinoma	2C12.02	Phase 2	[21]
SCH-442416	DMQ2K1V	N. A.	N. A.	Phase 1	[22]
AST-004	DM5WMG7	Stroke	8B20	Phase 1	[23]
BEMESETRON	DMSPJX9	N. A.	N. A.	Discontinued in Phase 3	[2]
BAY 60-6583	DMTEJV1	Myocardial ischemia	BA6Z	Preclinical	[24]
CF602	DM0ULO2	Inflammation	1A00-CA43.1	Preclinical	[21]
CF502	DMQSJ20	Inflammation	1A00-CA43.1	Preclinical	[21]

Drug(s) Targeting Glutamate receptor AMPA (GRIA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Halothane	DM80OZ5	Anaesthesia	9A78.6	Approved	[25]
E-2007	DMJDYNQ	Diabetic neuropathy	8C0Z	Approved	[26]
Zopiclone	DMPI6Z0	Insomnia	7A00-7A0Z	Approved	[27]
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[28]
Enflurane	DM0YJSB	Anaesthesia	9A78.6	Approved	[29]
Isoflurane	DMY6T31	Anaesthesia	9A78.6	Approved	[30]
Bromazepam	DMY9TCW	Anxiety disorder	6B00-6B0Z	Approved	[31]
Artemisinin SP	DMFETDK	Malaria	1F40-1F45	Approved	[32]
Dihydroergotoxine	DM5D6WZ	Alzheimer disease	8A20	Approved	[33]
Barbiturate	DMJIA6T	Anaesthesia	9A78.6	Approved	[34]

Drug(s) Targeting Glutamate receptor ionotropic kainate 2 (GRIK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SYM2081	DM30WDL	Discovery agent	N.A.	Investigative	[5]
dysiherbaine	DM0EBAF	Discovery agent	N.A.	Investigative	[5]
domoic acid	DMYPVO0	Discovery agent	N.A.	Investigative	[5]
2,4-epi-neodysiherbaine	DMZRY0Q	Discovery agent	N.A.	Investigative	[5]

Drug(s) Targeting Glutamate receptor ionotropic kainate 3 (GluK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SYM2081	DM30WDL	Discovery agent	N.A.	Investigative	[6]
dysiherbaine	DM0EBAF	Discovery agent	N.A.	Investigative	[6]
UBP310	DMVQL3J	Discovery agent	N.A.	Investigative	[35]

Drug(s) Targeting Glutamate receptor ionotropic kainate 1 (GRIK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Topiramate	DM82Z30	Alcohol dependence	6C40.2	Approved	[36]
LY293558	DM4N6EK	Pain	MG30-MG3Z	Phase 2	[37]
NS 1209	DM9EFH0	Epilepsy	8A60-8A68	Phase 2	[38]
NBQX	DMPHZI5	Neurological disorder	6B60	Phase 1	[39]
YM-90K	DMWRT4L	Convulsion	8A68.Z	Discontinued in Phase 2	[39]
[3H]quisqualate	DMDQBTX	Discovery agent	N.A.	Investigative	[40]
SYM2081	DM30WDL	Discovery agent	N.A.	Investigative	[4]
DNQX	DMQXPA5	Discovery agent	N.A.	Investigative	[16]
dysiherbaine	DM0EBAF	Discovery agent	N.A.	Investigative	[4]
domoic acid	DMYPVO0	Discovery agent	N.A.	Investigative	[4]

Drug(s) Targeting Glutamate receptor ionotropic kainate 4 (GluK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SYM2081	DM30WDL	Discovery agent	N.A.	Investigative	[7]
dysiherbaine	DM0EBAF	Discovery agent	N.A.	Investigative	[7]
domoic acid	DMYPVO0	Discovery agent	N.A.	Investigative	[7]

Drug(s) Targeting Glutamate receptor ionotropic kainate 5 (GRIK5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SYM2081	DM30WDL	Discovery agent	N.A.	Investigative	[8]
dysiherbaine	DM0EBAF	Discovery agent	N.A.	Investigative	[8]
domoic acid	DMYPVO0	Discovery agent	N.A.	Investigative	[8]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A3 receptor (ADORA3)	TTJFY5U	AA3R_HUMAN	Inhibitor	[2]
Glutamate receptor AMPA (GRIA)	TTAN6JD	NOUNIPROTAC	Inhibitor	[3]
Glutamate receptor AMPA 1 (GRIA1)	TTVPQTF	GRIA1_HUMAN	Inhibitor	[3]
Glutamate receptor ionotropic kainate 1 (GRIK1)	TT0MYE2	GRIK1_HUMAN	Agonist	[4]
Glutamate receptor ionotropic kainate 2 (GRIK2)	TT0K5RG	GRIK2_HUMAN	Agonist	[5]
Glutamate receptor ionotropic kainate 3 (GluK3)	TTNP6O2	GRIK3_HUMAN	Agonist	[6]
Glutamate receptor ionotropic kainate 4 (GluK4)	TTQV6BO	GRIK4_HUMAN	Agonist	[7]
Glutamate receptor ionotropic kainate 5 (GRIK5)	TTO6LI7	GRIK5_HUMAN	Agonist	[8]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4085).
• [2] 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96.
• [3] 1H-cyclopentapyrimidine-2,4(1H,3H)-dione-related ionotropic glutamate receptors ligands. structure-activity relationships and identification of pot... J Med Chem. 2008 Oct 23;51(20):6614-8.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450).
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 451).
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 452).
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 453).
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 454).
• [9] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [10] Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26.
• [11] Synthesis and AMPA receptor antagonistic activity of a novel 7-imidazolyl-6-trifluoromethyl quinoxalinecarboxylic acid with a substituted phenyl gr... Bioorg Med Chem Lett. 2004 Oct 18;14(20):5107-11.
• [12] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [13] New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists. Bioorg Med Chem Lett. 2006 Jan 1;16(1):167-70.
• [14] Substituted 1,2-dihydrophthalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor. J Med Chem. 1996 Jan 19;39(2):343-6.
• [15] Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl. 2013;(197):19-24.
• [16] Synthesis of chiral 1-(2'-amino-2'-carboxyethyl)-1,4-dihydro-6,7-quinoxaline-2,3-diones: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate recep... J Med Chem. 1996 Oct 25;39(22):4430-8.
• [17] Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
• [18] A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60.
• [19] 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
• [20] Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
• [21] 2011 Pipeline of Can-Fite BioPharm.
• [22] Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4.
• [23] Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. Stroke. 2022 Jan;53(1):238-248.
• [24] Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71.
• [25] Reduced inhibition of cortical glutamate and GABA release by halothane in mice lacking the K+ channel, TREK-1. Br J Pharmacol. 2007 Nov;152(6):939-45.
• [26] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [27] Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat. 2007 Aug;3(4):441-453.
• [28] Effects of sevoflurane on carrageenan- and fentanyl-induced pain hypersensitivity in Sprague-Dawley rats. Can J Anaesth. 2009 Feb;56(2):126-35.
• [29] Enflurane directly depresses glutamate AMPA and NMDA currents in mouse spinal cord motor neurons independent of actions on GABAA or glycine receptors. Anesthesiology. 2000 Oct;93(4):1075-84.
• [30] Transmembrane residues define the action of isoflurane at the GABAA receptor alpha-3 subunit. Brain Res. 2005 Jan 25;1032(1-2):30-5.
• [31] Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups. Psychopharmacology (Berl). 2009 May;204(1):61-71.
• [32] GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem. 2002 Aug;2(8):817-32.
• [33] Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97.
• [34] Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79.
• [35] Mapping the ligand binding sites of kainate receptors: molecular determinants of subunit-selective binding of the antagonist [3H]UBP310. Mol Pharmacol. 2010 Dec;78(6):1036-45.
• [36] Development of medications for alcohol use disorders: recent advances and ongoing challenges. Expert Opin Emerg Drugs. 2005 May;10(2):323-43.
• [37] Pharmacogenetics of new analgesics. Br J Pharmacol. 2011 Jun;163(3):447-60.
• [38] The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study. Anesth Analg. 2009 Apr;108(4):1311-9.
• [39] 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
• [40] Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotr... J Med Chem. 2008 Jul 24;51(14):4093-103.